Significance Of Microparticles In The Pathogenesis Of Liver Ischemia Reperfusion Injury
Funder
National Health and Medical Research Council
Funding Amount
$643,958.00
Summary
The overall aim of the project is to investigate the significance of microparticles in liver ischemia reperfusion injury (IRI). IRI causes damage to donor livers stored in preparation for liver transplantation. We postulate that microparticles released from the liver are critical in this form of injury. The expected outcomes are novel insights into liver IRI with the aim of developing new approaches to prevent liver damage during liver surgery, transplantation and shock.
Cholestasis And Hepatocyte Injury In Chronic Liver Disease
Funder
National Health and Medical Research Council
Funding Amount
$615,967.00
Summary
The aim of this project is to understand the consequences of long-term cholestasis or impaired bile excretion/flow on normal liver cells (hepatocytes) and to test whether specific bile acids can cause irreversible damage to hepatocytes leading to their transformation into pre-malignant cells and hepatocellular carcinoma (primary liver cancer). The results from this project will inform new strategies in screening, prevention and treatment of liver cancer in children and adults with cholestasis.
P53 And Hepatocyte Proliferation In Chronic Liver Disease
Funder
National Health and Medical Research Council
Funding Amount
$331,360.00
Summary
The aim of this project is understand how loss of control of p53, a tumour suppressor gene, in liver cells causes the transformation of normal liver cell (hepatocyte) to ‘rouge’ pre-cancerous cells in hepatocellular carcinoma (HCC) or primary liver cancer. We will test novel therapies to restore p53 function in liver cells in order to prevent or retard the development of HCC in patients with cirrhosis and those ‘at risk’ of this rapidly increasing fatal cancer in Australia.
MERTK Receptor Tyrosine Kinase: A Novel Therapeutic Target For Liver Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$870,972.00
Summary
Hepatic fibrosis is the principal cause of liver-related morbidity and mortality, for which there are no effective therapies. Thus, there is an urgent and unmet need to identify new targets to treat liver fibrosis. We have demonstrated for the first time, that liver fibrosis correlates with elevated hepatic expression of MERTK, a receptor tyrosine kinase. This project will explore whether MERTK function can be exploited to target and reverse liver fibrosis
Molecular And Cellular Pathogenesis Of Nonalcoholic Steatohepatitis: Insights From Human Studies
Funder
National Health and Medical Research Council
Funding Amount
$215,500.00
Summary
Nonalcoholic steatohepatitis (NASH) is the commonest cause for liver disease in Australia. On liver biopsy it is characterised by changes similar to that induced by alcohol, but occurs in individuals who consume minimal amounts of alcohol. The risk factors for the development of NASH include obesity, type II diabetes and hyperlipidemia. As the prevalence of obesity and diabetes are rapidly increasing in Australia, it is evident that NASH will become of major public health concern in the future. ....Nonalcoholic steatohepatitis (NASH) is the commonest cause for liver disease in Australia. On liver biopsy it is characterised by changes similar to that induced by alcohol, but occurs in individuals who consume minimal amounts of alcohol. The risk factors for the development of NASH include obesity, type II diabetes and hyperlipidemia. As the prevalence of obesity and diabetes are rapidly increasing in Australia, it is evident that NASH will become of major public health concern in the future. In those that develop liver disease from NASH, a proportion (10-30%) will develop advanced liver scarring leading to significant morbidity and mortality. The overall aim of this proposal is therefore to provide insight into why some people with fatty liver disorders develop NASH and to determine the basis for disease progression in this condition. Over the last decade, work at the Storr Liver Unit in a nutritional animal model of NASH has suggested potential mechanisms for disease progression in NASH. This proposal seeks to determine whether such mechanisms operate in human NASH by conducting studies in a large cohort of well chracterised patients with this disorder. Advances in molecular and cellular biology now permit such studies by anaylsis of small quantities of tissue such as that obtained at the time of liver biopsy. In this proposal we will examine both serum and liver tissue to characterise the role of oxidative stress (the biologic equivalent of rusting), the host immune response, liver cell injury and damage to the metabolic machinery within cells as determinants of diease severity in NASH. It is anticipated that these studies will provide the most comprehensive data to date on the pathogenesis of NASH and should suggest potential therapeutic targets for treating this condition.Read moreRead less
The Role Of The Hepatocyte And EMMPRIN In Liver Injury
Funder
National Health and Medical Research Council
Funding Amount
$607,487.00
Summary
This research plan investigates the role of the hepatocyte, the principal functional cell within the liver in the development of liver disease. Liver injury can result in end-stage scaring known as cirrhosis as well as leading to liver cancer. Our research aims to identify strategies for reversing the fibrotic process and result damage to the liver
Mitochondrial Dysfunction And Pathways Of Cell Death In Drug-induced Liver Injury
Funder
National Health and Medical Research Council
Funding Amount
$301,650.00
Summary
Drugs are an important cause of liver disease that can result in fatal liver damage or require liver transplantation. More than 500 drugs are reported to cause liver disease, but we know almost nothing about how drugs injure the liver. As well as prescribed drugs: panadol, either after self-poisoning or inadvertently taken in too high a dose in someone who is not eating or is taking other medications that interfere with panadol breakdown, is one of most common causes of acute liver failure. Furt ....Drugs are an important cause of liver disease that can result in fatal liver damage or require liver transplantation. More than 500 drugs are reported to cause liver disease, but we know almost nothing about how drugs injure the liver. As well as prescribed drugs: panadol, either after self-poisoning or inadvertently taken in too high a dose in someone who is not eating or is taking other medications that interfere with panadol breakdown, is one of most common causes of acute liver failure. Further, several herbal medicines have been implicated as causing liver disease. This project is designed to help us understand why and how 3 particular drugs damage the liver. We will study panadol, diterpenoids the active ingredients of skullcap, a herbal medicine, and azathioprine (imuran), a drug commonly used to suppress rejection after kidney or liver transplantation which occasionally causes very severe liver disease. Our main hypothesis is that these drugs damage mitochondria, the energy generating structures that form the engine of all living cells. We already know a little about how drug metabolites of panadol and the diterpenoids can damage mitochondria, but no-one has proven that this is the most important way in which they damage the liver. For drugs like azathioprine in which liver damage is rare, we are proposing that genetic defects in the mitochondrial DNA are what could predispose to liver injury. Thus our measurements will include how much mitochondrial DNA damage is caused by the drugs. Panadol, diterpenoids and azathioprine cause liver cell death by differing pathways (called apoptosis and necrosis). There are plausible ways in which mitochondrial damage could start off either (or both) cell death pathways during drug-induced liver injury, and we plan to test these. The new knowledge gained about how drugs damage the liver will be instrumental in allowing us to design new approaches to treat this important problem.Read moreRead less
Protecting Fatty Livers From Hepatic Ischemia-reperfusion Injury In Liver Surgery And Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$624,960.00
Summary
About one third of the population have a fatty liver, and this greatly increases risks of liver failure after liver surgery or when fatty donor livers are used for transplantation (such organs are currently disposed of). The disease process is called ischemia-reperfusion injury (IRI). The investigators have recently shown that both fibrates and statins provide partial protection against IRI in fatty livers. This research is directed at establish the protective mechanisms, and whether combination ....About one third of the population have a fatty liver, and this greatly increases risks of liver failure after liver surgery or when fatty donor livers are used for transplantation (such organs are currently disposed of). The disease process is called ischemia-reperfusion injury (IRI). The investigators have recently shown that both fibrates and statins provide partial protection against IRI in fatty livers. This research is directed at establish the protective mechanisms, and whether combination drugs are more effective.Read moreRead less
Studies Of The Role Of The Hepatocyte In The Response To HCV Infection
Funder
National Health and Medical Research Council
Funding Amount
$513,294.00
Summary
Infection with hepatitis C (HCV) affects 120 million individuals worldwide, and over 200,000 in Australia. HCV-related liver disease is the most common indication for liver transplantation in Australia and rates of HCV-related liver failure and hepatocellular cancer are predicted to increase as the HCV population ages. A new test for the IL28B gene, has shown to be the strongest predictor of cure after treatment. The mechanism of this association is unknown and is the subject of this grant.
Deciphering Mechanisms Of Liver Allograft Tolerance
Funder
National Health and Medical Research Council
Funding Amount
$520,964.00
Summary
The liver has paradoxical properties: it is the site of effective immune responses to pathogens, but under some circumstances, it is known to induce harmless immune responses. Liver transplants are more readily accepted than other organ grafts in the absence of immunosuppressive drugs but little is known about the mechanisms that prevent an effective response. This proposal aims to unravel these mechanisms. This project will have important implications for transplantation studies.